Premier Nutrition: The Protein Shake Company the FTC Found Making Joint Health Claims Its Own Studies Didn't Support

Premier Nutrition Corporation, the maker of Premier Protein protein shakes and related nutritional products, reached a settlement with the Federal Trade Commission resolving charges that the company made arthritis treatment and joint health claims about its protein shake products that were not supported by competent and reliable scientific evidence — with the FTC's investigation finding that Premier Nutrition's own commissioned studies had failed to show the claimed therapeutic effects on joint pain and function.DOCUMENTED

The case highlighted a recurring pattern in dietary supplement and functional food enforcement: companies that commission studies hoping to support health claims for their products may be using those studies in advertising even when the study results do not actually support the claims being made — or when the studies have significant methodological limitations that undermine the strength of the evidence they purport to provide.

The FTC's Substantiation Standard

The FTC's substantiation requirement for health claims in advertising requires that the evidence supporting the claim be competent and reliable scientific evidence — a standard that in the health claim context typically means well-controlled human clinical studies that show the claimed effect with statistical significance in a representative study population. The standard is not satisfied by preliminary research, mechanistic theory, animal studies, or single small studies whose results have not been replicated — and it is specifically not satisfied by studies that failed to show the claimed effect, even if those studies contain some subgroup analyses or secondary endpoints that trend in a favorable direction.REVIEWED

Premier Nutrition's situation — where the company had commissioned studies that it then used in advertising despite the studies failing to support the primary claims — is a textbook application of the FTC's substantiation standard. The existence of a study is not the same as evidence supporting a claim; a failed study is evidence against the claim, not for it. When a company continues to make a claim that its own evidence has failed to support, the FTC treats the claim as unsubstantiated because the company has had actual notice, through its own research program, that the evidence base does not support the advertising.DOCUMENTED

Joint Health Claims in the Protein Category

The marketing of joint health benefits for protein shake products exploits consumer understanding of protein's role in muscle and tissue maintenance. Many consumers understand that protein is necessary for tissue repair and muscle function, and claims suggesting that a protein product supports joint health benefit from this general understanding without necessarily specifying a mechanism that the claimed product actually demonstrates. The shift from a claim like 'protein supports muscle function' — which has a legitimate scientific basis — to 'our protein shake helps with arthritis' requires a specific demonstration that the particular product, at the dose consumed as directed, produces a therapeutic effect on joint inflammation or function in people with arthritis.REVIEWED

This distinction — between claims supported by the general nutritional properties of an ingredient category and claims about specific therapeutic effects at product doses — is the core of the FTC's analysis in many functional food and supplement advertising cases. Companies frequently slide from the former to the latter without recognizing that the evidentiary standard changes substantially when a claim becomes specific and therapeutic rather than general and nutritional. Premier Nutrition's claims crossed this line by making specific arthritis and joint health benefit claims that required clinical evidence the company did not have.

Commissioning a study to see if your claim is true and then advertising the claim anyway when the study says it is not is not a research program. It is a paperwork exercise followed by false advertising.

The Consumer Refund Component

The class action settlement that ran parallel to the FTC's enforcement action provided for consumer refunds to purchasers who had bought Premier Nutrition products in reliance on the joint health claims during the class period. Class members could submit claims for cash reimbursement up to a specified per-person cap, funded from the settlement fund. The consumer refund mechanism in cases like this has limitations: awareness of the settlement among affected consumers is typically low, claims rates are modest relative to the number of affected purchasers, and the per-claimant payment may be smaller than the full amount spent on products purchased in reliance on the false claims.DOCUMENTED

Despite these limitations, the consumer refund component serves an important function in the FTC's enforcement toolkit because it provides direct compensation to identified consumers rather than channeling the entire recovery to the government — a distribution that more directly addresses the actual harm to individuals who purchased products based on false claims. For consumers who purchased Premier Nutrition products because of the arthritis or joint health claims and who receive compensation through the settlement, the recovery is modest relative to the harm, but it represents an acknowledgment that they were deceived and an attempt to make them partially whole for the cost of products that did not deliver what was advertised.

How the FTC Evaluates Weight and Joint Health Claims

The FTC's approach to evaluating health benefit claims for food and supplement products focuses on what a reasonable consumer would take away from the overall marketing presentation, not merely on whether individual statements are technically accurate. A marketing campaign that prominently features testimonials from people who experienced improved joint function, that displays imagery of active individuals moving freely after product use, and that uses qualifying language in small print to hedge the specific claims, may nonetheless create an overall impression that the product produces the depicted benefits — an impression the FTC evaluates against the competent and reliable scientific evidence standard. The agency's health claims policy documents make clear that the number of studies required to substantiate a claim, their quality, and the consistency of their results all affect the adequacy of the evidence base. For joint health claims specifically — an area where the nutritional science is contested and where large, well-controlled trials have frequently failed to replicate smaller studies' positive findings — the evidence threshold the FTC applies is demanding. Companies marketing joint health benefits for protein or supplement products should ensure that their substantiation file contains the type of human clinical evidence that could withstand FTC scrutiny, not merely mechanistic research or animal studies that show plausible pathways without demonstrating the claimed outcome in human populations at the product's recommended dose.

Have documents relevant to this story? Reach us through our tips channel.